title: The effect of Jeo Dang-Tang on cytokines production in the patients with cerebral infarction.
abstract: The herbal formulation "Jeo Dang-Tang" (JDT) has long been used for various cerebrovascular diseases. However, very little has scientific investigation been carried out. The aim of the present study is to investigate the effect of JDT on the production of various cytokines in the patients with cerebral infarction (CI). Peripheral blood mononuclear cells (PBMC) obtained from the patients with CI were cultured for 24h in the presence or absence of lipopolysaccharide (LPS) or phytohemagglutinin (PHA). The amount of interleukin (IL)-4, IL-10 and transforming growth factor (TGF)-1beta, in culture supernatant, was significantly increased in the JDT, LPS or PHA treated cells compared to unstimulated cells (P < 0.05). We also show that increased IL-4, and IL-10 level by LPS or PHA was significantly inhibited by JDT in a dose-dependent manner. Maximal inhibition rate of IL-4 and IL-10 production by JDT was 45 +/- 2% and 51 +/- 5% for LPS-stimulated cell and 41.5 +/- 3% and 70.8 +/- 2% for PHA-stimulated cells, respectively (P < 0.05). On the other hand, JDT significantly increased the LPS or PHA-induced TGF-beta1 production (P < 0.05). These data suggest that JDT has a regulatory effect on the cytokines production, which might explain its beneficial effect in the treatment of CI.
authors.affiliation: Department of Pharmacology, College of Oriental Medicine, Kyung Hee University, Dongdaemun-Gu, Seoul, Republic of Korea.
authors.forename: Hyun-Ja
authors.initials: HJ
authors.lastname: Jeong
authors.forename: Sei-Young
authors.initials: SY
authors.lastname: Kang
authors.forename: Sang-Yong
authors.initials: SY
authors.lastname: Kim
authors.forename: Sang-Gwan
authors.initials: SG
authors.lastname: Lee
authors.forename: Sung-Geun
authors.initials: SG
authors.lastname: Lee
authors.forename: Kang-Keyng
authors.initials: KK
authors.lastname: Sung
authors.forename: Hyung-Min
authors.initials: HM
authors.lastname: Kim
mesh_terms: D002544:Cerebral Infarction / Q000188:drug therapy / Q000276:immunology*; D016207:Cytokines / Q000096:biosynthesis*; D006801:Humans; D066298:In Vitro Techniques; D016753:Interleukin-10 / Q000096:biosynthesis; D015847:Interleukin-4 / Q000096:biosynthesis; D007963:Leukocytes, Mononuclear / Q000187:drug effects / Q000276:immunology; D008070:Lipopolysaccharides / Q000494:pharmacology; D010835:Phytohemagglutinins / Q000494:pharmacology; D008517:Phytotherapy; D010936:Plant Extracts / Q000494:pharmacology*; D016212:Transforming Growth Factor beta / Q000096:biosynthesis; D053773:Transforming Growth Factor beta1
chemical_list: D016207:Cytokines; D008070:Lipopolysaccharides; D010835:Phytohemagglutinins; D010936:Plant Extracts; C508960:TGFB1 protein, human; D016212:Transforming Growth Factor beta; D053773:Transforming Growth Factor beta1; D016753:Interleukin-10; D015847:Interleukin-4